932results about "Growth factors/regulators" patented technology

The present invention relates to a method for the production and purification of a protein of interest, and more particularly, the present invention relates to a fusion protein comprising: a self-aggregating peptide, a linker peptide comprising an amino acid sequence selected from an elastin-like polypeptide (ELP) or a protease propeptide (ProP) and the spacer comprising a cleavage site, and a protein portion of interest, and a method for column-free one-step purification of a target protein by expressing the fusion protein.

The present disclosure provides a nucleic acid molecule (e.g., a plasmid or vector) comprising: a nucleic acid sequence encoding a bicistronic or polycistronic LAMP construct comprising a specific fragment of an LAMP endodomain and an antigen domain heterologous to the LAMP protein to provide at least one antigen for eliciting an immune response, wherein the antigen expressed by the construct is optionally processed and presented to a class II MHC molecule; and a nucleic acid sequence encoding an immune response enhancing polypeptide, optionally secreted from a host cell. The nucleic acid molecules can be used, for example, for the treatment of diseases, in particular allergy, infectious diseases, diabetes, hyperproliferative disorders and / or cancer.

The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.

The invention relates to the technical field of medical instruments, and discloses an application of a collagen-gelatin combined VEGF (vascular endothelial growth factor) mimic peptide in promoting growth of blood vessels, the collagen-gelatin combined VEGF mimic peptide is QKCMP-Enhancer, and the sequence of the collagen-gelatin combined VEGF mimic peptide is Ac-KLTWQELYQLKYKGI-(GPO) 5-(KR) 4-(RGD) 4-(KR) 4-GGG-(Gly) 3-NH2. The invention discloses a collagen-gelatin combined VEGF (vascular endothelial growth factor) mimic peptide which shows remarkable biological activity in the aspects of promoting angiogenesis, stimulating cell proliferation and inhibiting cell apoptosis. A new way and a new strategy are developed for treating related diseases; the collagen-gelatin is combined with the VEGF mimic peptide, so that a safer, more efficient and controllable angiogenesis method can be realized, and the collagen-gelatin combined VEGF mimic peptide has remarkable clinical application potential.

Disclosed herein are extracellular vesicles comprising an immunomodulating component. Also provided are methods for producing the extracellular vesicles and methods for using the extracellular vesicles for treating cancer, GvHD, and autoimmune diseases.

Compounds for the delivery of progranulin, a progranulin fragment, and / or at least one granulin protein subunit across the blood brain barrier. Compounds for the delivery of progranulin, a progranulin fragment, and / or at least one granulin protein subunit across the blood brain barrier, the compounds including a progranulin domain, a TfR1 binding domain, and optionally an albumin binding domain. Compounds for the delivery of wildtype or unmodified progranulin across the blood brain barrier.

The invention belongs to the technical field of medical equipment, and particularly relates to a blood growth factor extraction device and an information loading system.The blood growth factor extraction device comprises a box body used for connecting all components; the blood centrifugal assembly is arranged in the box body, and the blood centrifugal assembly is used for centrifugally removing red blood cells of the blood; the information field assembly is arranged in the box body, the information field assembly is connected with the blood centrifugal assembly, and the information field assembly is used for performing scalar wave action on blood in the blood centrifugal assembly and loading specific life factor information into plasma; the disinfection assembly is arranged in the box body, the disinfection assembly is connected with the blood centrifugal assembly, the disinfection assembly is used for disinfecting test tubes in the blood centrifugal assembly, and it is guaranteed that wound repair factors, blood platelets, growth factors and the like are more easily and sufficiently separated during separation and preparation.

The invention belongs to the field of medicines, and discloses application of a protein polymer in preparation of a medicine for treating autism. The inventor finds that a protein polymer generated after mesenchymal stem cells are stimulated by a stress environment, such as ultraviolet radiation, has a certain treatment effect on autism, and provides possibility for treatment of autism.

The invention belongs to the technical field of gene engineering, and relates to a construction method of a mouse model capable of rapidly degrading MSTN protein, which comprises the following steps: sequentially inoculating a 5'homologous arm, 3xEAAAK, an FKBP1A gene synonymous mutation sequence, 3xEAAAK, a red fluorescent protein mCherry sequence and a 3 'homologous arm on a Donor vector to obtain a Donor recombinant vector; designing gRNA based on a third exon of the Mstn gene, mixing the gRNA, Cas9 protein and a Donor recombinant vector, injecting the mixture into a mouse fertilized egg, and performing in-vitro culture and transplantation to obtain an F0-generation mouse; and hybridizing the F0-generation mouse with a wild type, or continuously breeding the filial generation to obtain the knock-in mouse model. According to the invention, a dTAG targeted protein degradation technology is utilized, the obtained homozygous knock-in mouse is subjected to dTAG administration, and rapid and reversible degradation and removal of MSTN protein can be realized.

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

The invention belongs to the field of medicines, and discloses application of a stress-induced stem cell extract in treatment of cerebral apoplexy. The inventor finds that stem cells are cultured under proper stress conditions through screening, and the separated stem cell extract (also known as Alritoin) can increase the axon length and dendritic length of normal primary neurons and is beneficial to growth and conduction of nerve fibers; in a pdMCAO model, the volume of cerebral infarction in the acute stage of ischemia of a mouse can be remarkably reduced, the neurological function score can be improved, and a relatively good improvement trend is achieved in the aspect of cognition; in the acute stage of cerebral ischemia reperfusion, the pharmaceutical composition has remarkable effects on reducing the cerebral infarction volume of a mouse, reducing relative edema and improving the neurological function, and is relatively long in medication time window; in a cerebral ischemia reperfusion model, the trend of improving local cerebral blood flow is shown. The allitoin is expected to be developed into a promising drug for cerebral apoplexy, especially a drug for treating ischemic cerebral apoplexy.

The invention relates to a human recombinant GDF15 protein and application thereof in preparation of drugs for preventing and treating sepsis acute kidney injury, and belongs to the technical field of biological medicines. In order to solve the problem that an effective prevention and treatment scheme for improving SA-AKI by inhibiting oxygen death is lacked in existing clinical and research, the invention provides a human recombinant GDF15 protein of which the coding gene nucleotide sequence is shown as SEQ ID No: 1. Animal experiment results show that by intraperitoneal injection of the human recombinant GDF15 protein, kidney inflammation of sepsis mice can be relieved, and expression of PGAM5 can be down-regulated. Cell experiment results show that when the human recombinant GDF15 protein is given, LPS-induced USF2 increase can be inhibited. The human recombinant GDF15 protein provided by the invention can improve SA-AKI by inhibiting oxygen death and inflammation, provides a new idea and an intervention target for prevention and treatment of SA-AKI, and shows a good clinical application prospect.

An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8 or 9; boric acid at a concentration of 0.01 mM-923 mM; and a non-ionic tonicity agent. The pH value is around 5.5-8.4. The non-ionic tonicity agent is glycerin, sucrose, mannitol, or sorbitol. A concentration of the PDSP is 0.01%-1% w / v.

The present disclosure provides a composition comprising a nucleic acid sequence encoding from about 1 to about 100 amino acid sequences, the amino acid sequences being tumor-specific antigens wherein at least one tumor-specific antigen is an amino acid sequence associated with the WNT pathway. In some embodiments, the nucleic acid sequence encodes from about 20 to about 60 tumor specific antigens; wherein from about 1 to about 8 tumor specific antigens are selected from one or a combination of the following: WNT, CTNNB1, AXIN1, AXIN2, APC, CK1, and GSK3B. Also provided is a cell comprising any one or more compositions disclosed herein and a pharmaceutical composition comprising: (i) a therapeutically effective amount of one or more compositions as disclosed herein; and (ii) a pharmaceutically acceptable carrier. A method of treating cancer in a subject in need thereof is also provided.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention discloses a construction method and application of an iPSC-derived mesenchymal stem cell strain for overexpressing a VEGFA gene based on a CRISPR / Cas9 technology, and relates to the technical field of biological cells, the construction method of the iPSC-derived mesenchymal stem cell strain for overexpressing the VEGFA gene based on the CRISPR / Cas9 technology comprises the following steps: S1, designing sgRNA and ssDNA for an insertion site AAVS1, and detecting the cutting efficiency of the sgRNA; s2, introducing a CRISPR (clustered regularly interspaced short palindromic repeats) system into the cells in an electroporation manner to obtain an iPSC cell strain into which an exogenous gene VEGFA is inserted at a fixed point; s3, carrying out directional induced differentiation on the iPSC cell strain to the iMSC to obtain an iMSC cell strain with overexpression of VEGFA (Vascular Endothelial Growth Factor A) protein; the iMSC of the overexpressed VEGFA protein can well stimulate vascular endothelial growth and promote angiogenesis, and more possibilities are provided for repair treatment of ischemia-related diseases.

Heterodimeric antibody FC-containing proteins, such as bispecific antibodies, are provided. [Solution] Provided is a heterodimeric protein comprising a first polypeptide comprising a first Fc region of an immunoglobulin, wherein the first Fc region comprises a first CH3 region, and a second polypeptide comprising a second Fc region of an immunoglobulin, wherein the second Fc region comprises a second CH3 region, wherein the sequences of the first and second CH3 regions are different and the heterodimeric interaction between the first CH3 region and the second CH3 region is stronger than each of the homodimeric interactions of the first CH3 region and the second CH3 region.

The invention belongs to the technical field of biological medicine, and provides an engineered extracellular vesicle, a preparation method, application and a drug for targeted repair of blood brain barrier in order to solve the technical problems that an existing repair tool takes effect slowly and is not enough in specificity, and the engineered extracellular vesicle is loaded with Wnt7a-K190A protein. After entering the brain, the engineered extracellular vesicle can be rapidly and specifically combined with a Gpr124 receptor to promote blood brain barrier repair, and in-vivo experiments verify that the engineered extracellular vesicle can promote blood brain repair, so that the engineered extracellular vesicle can be applied to preparation of targeted blood brain barrier repair drugs, becomes a supplement of existing tools, AAV, LNP and the like, and has a wide application prospect. Particularly, the high requirement on the treatment timeliness of central nervous system (injury irreversibility) diseases is met.

Disclosed herein are polypeptides that bind to mesothelin and methods of use thereof.

The present disclosure relates to methods and materials for neurotrophic factor 3 (NT-3) gene therapy. The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of NT-3 polynucleotides. The present disclosure provides rAAVs and methods of using the rAAVs for NT-3 gene therapy to improve muscle strength, stimulate muscle growth, and treat muscle consumption disorders such as muscular dystrophy and fibula amyotrophic neuropathy.

To achieve in vivo repair of severed mammalian nerve tissue, a system can be employed to induce distraction neurogenesis. At least a portion of the system can be anchored at an injury site, such as between distal and proximal nerve ends. The system can be attached to the proximal nerve end and can place the nerve under micro-tension for an extended period of treatment. The system may also deliver medication or treatment to encourage neurogenesis and to reduce pain in the subject receiving treatment. After the course of treatment, the device can be removed from the injury site, and the nerve ends rejoined.

Provided herein are polypeptide compositions and chimeric antigen receptors comprising natural ligands of hematopoietic cell receptors and are thereby able to specifically bind to hematopoietic cell receptors. Also provided are methods and compositions for using the polypeptide compositions and chimeric antigen receptors in the treatment of disease, such as cancer, for editing a gene in a cell, and for culturing populations of cells.

To provide genome editing systems and related methods which allow for treatment of Hyper IgM Syndrome, a group of disorders characterized by defective CD40 signaling.SOLUTION: Provided herein is an isolated oligonucleotide donor template which comprises, from 5' to 3', A1-N-UTR-pA-A2, where A1 is a homology arm that is substantially identical to a first homology arm of a target CD40L nucleic acid; N is a cargo comprising one or more of exons 2-5 of a CD40L gene; UTR is a CD40L 3' untranslated region (UTR); pA is a polyA tail; and A2 is a homology arm that is substantially identical to a second homology arm of the target CD40L nucleic acid.SELECTED DRAWING: None

To provide methods and compositions of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response to a vaccine for an infectious substance.SOLUTION: Provided is a method comprising administering a herpesvirus entry mediator (HVEM) agonist, a tumor necrosis factor superfamily 14 (TNFSF-14) agonist, or a combination thereof.SELECTED DRAWING: Figure 1A

The present disclosure relates to compositions and methods of treating stroke, reducing neuroinflammation, and generating new neurons in a primate using an adeno-associated viral (AAV) vector encoding NeuroD1.

The present invention relates to the field of antibodies. In particular, the present invention relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2 / ErbB-3 positive cells. More particularly, the present invention relates to the treatment of cells containing an NRG1 fusion gene that includes at least a portion of the NRG1 gene fused to sequences from a different chromosomal location.

The present invention provides, among other things, compositions and methods for reducing oxidation of a complex comprising insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), for treating diseases and complications of prematurity. In some embodiments, the methods comprise adding antioxidants. In some embodiments, the antioxidants are methionine or sodium thiosulfate. In some aspects, the compositions provided are stable, pure and potent compositions comprising IGF-1 and IGFBP-3. In some aspects, the formulation is lyophilized.

A polypeptide complex, a protein, a nucleic acid, a composition and uses thereof. A cell specific high expression and long retention (ePR) strategy is employed to overexpress specific mRNA in hepatic stellate cells into therapeutic proteins and to promote long-term anchoring of the therapeutic proteins in a fibrotic matrix microenvironment. The first-generation and second-generation retinol derivatives containing carboxyl are determined, can partially replace cholesterol in lipoid nanoparticles (LNP), and are enriched in a fibrosis area through intravenous injection, so that the expression of mRNA in a fibrosis liver is improved by about 10 times. Furthermore, therapeutic mRNA has been engineered by coupling the gene sequence of the collagen binding domain (CBD) to the C-terminus of the therapeutic protein. In screening, it is found that the peptide sequence of placental growth factor (PLGF) shows the strongest collagen affinity, the liver residence time of overexpressed therapeutic protein can be prolonged, and systemic side effects are reduced to the minimum.

This disclosure relates to cell therapy approaches for treating progranulin (PGRN) deficiencies with human induced pluripotent stem cell (hiPSC)-derived cells. Advantageously, the hiPSC-derived cells (e.g., microglia progenitor cells) described herein can cross-correct PGRN deficiencies in damaged or diseased cells while reducing the amount of endogenous cell ablation that is needed, as demonstrated by experimental results showing restoration of PGRN levels in GRN mutant cells and brain organoids.